Europe has a remarkable tradition of clinical thought leaders who develop major new medical device technologies. In cardiology, the first angioplasty, coronary stent, and percutaneous heart valve procedures were all performed in Europe, as were the first spinal implants, just to name a few. Yet European device company start-up activity lags far behind the rate of clinical breakthroughs. There are several reasons for this, including the lack of sufficient numbers of experienced company executives to run these companies, the reluctance of academic clinicians to commercialize their new technology ideas, and the dearth of European venture capital willing to back these start-ups. Matignon Technologies, a Paris-based venture fund, sees this gap in financing of European device start-ups as an opportunity, and has just launched one of the largest European funds dedicated primarily to medical technology.
Matignon Launches Major New European Device Fund
Europe has a remarkable tradition of clinical thought leaders who develop major new medical device technologies. Yet European device company start-up activity lags far behind the rate of clinical breakthroughs. There are several reasons for this, including the dearth of European venture capital willing to back these start-ups. Matignon Technologies sees this gap in financing of European device start-ups as an opportunity, and has just launched one of the largest European funds dedicated primarily to medical technology.
More from Europe
US President Trump has imposed sweeping tariffs that encompass medtech. These are expected to drive up costs, disrupt supply chains and hinder innovation, likely driving the EU to seek new trade partnerships to mitigate the impact.
Medtech has not yet been spared from the Trump administration’s trade tariffs, which, for UK exporters will be 10% – half the rate applied to EU27 exporters.
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.
More from Geography
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.